Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression

Arthritis and Rheumatism
Philip J MeaseWayne Tsuji

Abstract

Etanercept has been shown to improve the articular and cutaneous manifestations of psoriatic arthritis (PsA). In this study, we further evaluated the safety, efficacy, and effect on radiographic progression of etanercept in patients with PsA. Patients with PsA (n = 205) were randomized to receive placebo or 25 mg etanercept subcutaneously twice weekly for 24 weeks. Patients continued to receive blind-labeled therapy in a maintenance phase until all had completed the 24-week phase, then could receive open-label etanercept in a 48-week extension. Efficacy and safety were evaluated at 4, 12, and 24 weeks and at 12-week intervals thereafter. Radiographs of the hands and wrists were assessed at baseline and 24 weeks, at entry to the open-label phase, and after 48 weeks in the study. Etanercept significantly reduced the signs and symptoms of PsA and psoriasis. At 12 weeks, 59% of etanercept patients met the American College of Rheumatology 20% improvement criteria for joint response, compared with 15% of placebo patients (P < 0.0001), and results were sustained at 24 and 48 weeks. At 24 weeks, 23% of etanercept patients eligible for psoriasis evaluation achieved at least 75% improvement in the Psoriasis Area and Severity Index, compa...Continue Reading

References

Jan 1, 1978·Dermatologica·T Fredriksson, U Pettersson
Feb 1, 1990·British Journal of Rheumatology·M FarrP A Bacon
Jan 1, 1973·Seminars in Arthritis and Rheumatism·J M Moll, V Wright
Nov 1, 1984·British Journal of Rheumatology·R ScarpaC Biondi Oriente
Feb 1, 1980·Arthritis and Rheumatism·J F FriesH R Holman
Apr 1, 1994·Clinical and Experimental Immunology·P EttehadiR D Camp
Nov 15, 1997·Rheumatic Diseases Clinics of North America·M L Cuellar, L R Espinoza
Aug 26, 1998·British Journal of Rheumatology·P RahmanD Salonen
Mar 13, 1999·Annals of Internal Medicine·L W MorelandM E Weinblatt
Nov 30, 2000·The New England Journal of Medicine·J M BathonB K Finck
Jun 25, 1949·Journal of the American Medical Association·O STEINBROCKERR C BATTERMAN

❮ Previous
Next ❯

Citations

Sep 6, 2013·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Marina Papoutsaki, Antonio Costanzo
Sep 1, 2005·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·R Mössner, K Reich
Oct 1, 2011·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·M A RadtkeM Augustin
Feb 28, 2006·Zeitschrift für Rheumatologie·J Braun, S Wassenberg
Oct 6, 2006·Archives of Dermatological Research·Ulrich MrowietzJonathan Barker
Sep 10, 2011·Archives of Dermatological Research·Nicole F VelezAbrar A Qureshi
Jul 2, 2011·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Ewen CumminsYogesh Suresh Punekar
Apr 8, 2010·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Andrea Picchianti-DiamantiBruno Laganà
Jul 28, 2005·Current Rheumatology Reports·Eric M Ruderman
Feb 2, 2012·Clinical Reviews in Allergy & Immunology·Allen Anandarajah
Jun 19, 2013·American Journal of Clinical Dermatology·Wolf-Henning Boehncke, Alan Menter
Apr 13, 2013·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Emily Yiping GanHong Liang Tey
Jun 28, 2011·Annales de dermatologie et de vénéréologie·H BachelezS Boulinguez
Mar 1, 2006·Reumatología clinica·UNKNOWN Comité Mexicano del Consenso de Biológicos. Colegio Mexicano de Reumatología
Feb 3, 2005·Nature Reviews. Drug Discovery·Alice B Gottlieb
Sep 14, 2011·Nature Reviews. Rheumatology·Caroline A ChangPaul F Lizzul
Jun 29, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·George S DeepeJames S Louie
Jan 20, 2009·Rheumatology·J A Singh, V Strand
Feb 22, 2012·Rheumatology·Gabrielle H KingsleyDavid L Scott
Apr 20, 2005·Current Opinion in Rheumatology·Allen Anandarajah, Christopher T Ritchlin
Jun 16, 2005·Current Opinion in Rheumatology·Jane Zochling, Jürgen Braun
Jun 16, 2005·Current Opinion in Rheumatology·Philip J Mease
Jun 10, 2006·Current Opinion in Rheumatology·Filip Van den BoschHerman Mielants
Apr 4, 2009·Current Opinion in Rheumatology·Alexandra Villa-Forte
May 23, 2009·Current Opinion in Rheumatology·Philip J Mease
Jun 29, 2011·Current Opinion in Rheumatology·Matthew L Stoll, Marilynn Punaro
Jan 5, 2011·International Journal of Rheumatic Diseases·Fabrizio CantiniEmanuele Cassarà
Apr 9, 2013·Annals of the Rheumatic Diseases·Karen Minde FagerliTore K Kvien
Feb 15, 2005·Annals of the Rheumatic Diseases·D van der HeijdeD D Gladman
Jan 29, 2005·Annals of the Rheumatic Diseases·C AntoniUNKNOWN IMPACT 2 Trial Investigators

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.